Companies
Nutrasource
confirmed via its own domain's case coverage of advancing CBD innovation through regulatory-strategy-to-clinical-execution work with DSM-Firmenich, and independent Nutritional Outlook coverage of how the SGS Nutrasource brand serves the industry through certifications, clinical trials, and consumer-trust practice.
- Country
- Canada
Regulatory-to-clinical
Coverage
| EU | US | |
|---|---|---|
| market-access-commercial | ✓ | ✓ |
Regulatorsfda
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | approximately CAD 20 million (2022-12-31) | sgs.com |
| Headcount | over 150 employees worldwide (2023-05-11) | nutrasource.ca · sgs.com |
| Production site | four sites in North America (2023-05-11) | nutrasource.ca |
| Certification | NutraStrong, IFOS, IGEN, IPRO, ICAP, IKOS, IAOS, and Radioactivity Tested & Certified programs | nutrasource.ca · sgs.com |
| Regulatory approval | Institution-wide Cannabis Research Licence and Controlled Drugs and Substances Dealer’s Licence from Health Canada | nutrasource.ca |
| Funding | Majority stake acquired by SGS in 2023 medium confidence | sgs.com |
Independent sources: sgs.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Health-claim substantiation (EFSA 13/14) | market-access-commercial | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.